VOLUME 3 , ISSUE 2 ( July-December, 2019 ) > List of Articles
Rajat Sharma, Mohit Sharma, Sanchit Bansal, Karaninder Singh, Neeti R Singh
Keywords : Myxoid areas, Radical treatment, Retroperitoneal liposarcoma, Soft-tissue sarcomas
Citation Information : Sharma R, Sharma M, Bansal S, Singh K, Singh NR. A Huge Retroperitoneal Liposarcoma: A Case Report. Curr Trends Diagn Treat 2019; 3 (2):90-92.
DOI: 10.5005/jp-journals-10055-0077
License: CC BY-NC 4.0
Published Online: 18-07-2020
Copyright Statement: Copyright © 2019; The Author(s).
Aim: Retroperitoneal soft-tissue sarcomas are relatively uncommon diseases, and the most frequent histotype, ranging from 20 to 45% of all cases, is represented by liposarcoma, which is a hard-to-treat condition for its local aggressiveness and clinical aspecificity. Presentation of case: We report a case of a 69-year-old woman who underwent surgical resection for a giant pleomorphic retroperitoneal liposarcoma. Discussion: Currently, chemotherapy for retroperitoneal soft-tissue sarcomas is not effective, and radiotherapy has limited efficacy due to the toxicity affecting adjacent intra-abdominal structures and showed validity only in case of high-grade malignancy by reducing local recurrence but with no advantage in overall survival. Nowadays, complete surgical resection remains the most important predictor of local recurrence and overall survival. Conclusion: The removal of a retroperitoneal sarcoma of remarkable size is a challenge for the surgeon owing to the anatomical site, the absence of an anatomically evident vascular-lymphatic peduncle, and the adhesions contracted with the contiguous organs and great vessels. Therefore, we believe that, particularly for large-sized diseases associated with high-grade malignancy, a complete surgical resection with the removal of the contiguous intra- and retroperitoneal organs when infiltrated represents the only therapeutic option to obtain a negative margin and therefore an oncological radicality.
© Jaypee Brothers Medical Publishers (P) LTD.
We use cookies on this site to enhance your user experience.
By clicking any link on this page you are giving your consent for us to set cookies.